Keck USC 9th Annual Southern California Kidney Symposium 2025

KECK USC 9TH ANNUAL SOUTHERN CALIFORNIA KIDNEY SYMPOSIUM 2025

Join us on Friday, June 6, 2025, from 8:00 AM to 4:00 PM at the Aresty Conference Center, USC Health Sciences Campus, Los Angeles, CA, for the Ninth Annual Southern California Kidney Symposium. This premier educational event is dedicated to the theme of “Updates on Biologics and Novel Therapeutics for Kidney Diseases.”

With 11 videos, 11 audios, 11 file sub vtts, and 2 PDFs, this comprehensive course offers over 4.32 GB of expert content from leading faculty at USC and other top U.S. academic institutions. Learn about the latest research findings and management strategies in areas such as hypertension, advanced CKD, ESKD, glomerular diseases, onco-nephrology, and kidney transplantation.

Course Objectives:

• Discuss the roles of new drug therapies in managing hypertension, hyperphosphatemia, and anemia in CKD.
• Compare newly emerging therapies for IgA nephropathy.
• Outline diagnostic and therapeutic options for membranous nephropathy.
• Summarize therapeutic options for lupus nephritis and C3 glomerulopathy.
• Identify new therapies for APOL1-mediated chronic kidney disease.
• Recognize renal side effects of targeted cancer therapies.
• Analyze treatment strategies for kidney transplant rejection.

👩‍⚕️ Who Should Attend

• Nephrologists and kidney specialists managing chronic kidney disease, glomerular disorders, and transplant patients.
• Internal medicine physicians and hospitalists who co‑manage patients with renal complications.
• Advanced practice providers (NPs, PAs) working in nephrology or internal medicine.
• Researchers and translational scientists studying biologics and novel therapeutics in renal medicine.
• Residents and fellows in nephrology or internal medicine preparing for board exams or expanding their clinical knowledge.

Topics:

• 01 Microangiopathic Hemolytic Anemia Focus on Thrombotic Thrombocytopenic Purpura aTypical Hemolytic Uremic Syndrome
• 02 Novel Therapies in APOL-Mediated Kidney Disease – From Molecular Pathways to Therapeutic Options
• 03 Hypertension and Endothelin Inhibition – A New Option for Resistant Hypertension
• 04 New Therapeutic Options in ESKD Patients for Hyperphosphatemia
• 05 Hypoxia-Inducible Factor Activation in Anemia Due to Chronic Kidney Disease
• 06 Overview of New Therapies for Glomerular Diseases and the Treatment of IgA Nephropathy
• 07 Emerging Therapies and Strategies for the Management of Membranous Nephropathy
• 08 Expanded Therapeutic Options and Targets for the Treatment of Lupus Nephritis
• 09 Importance of Genetic Factors and Emerging Therapeutic Options for C3 Glomerulopathy
• 10 Immune Checkpoint Inhibitor Induced AKI (ICI-AKI)
• 11 Emerging Biologics for Antibody Mediated Rejection in Kidney Transplantation